T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study.
Viktor Grünwald,Thomas Powles,Evgeny Kopyltsov,Vadim V. Kozlov,Teresa Alonso-Gordoa,Masatoshi Eto,Thomas E. Hutson,Robert J. Motzer,Eric Winquist,Pablo Maroto,Bhumsuk Keam,Giuseppe Procopio,Shirley Wong,Bohuslav Melichar,Frederic Rolland,Mototsugu Oya,K. Rodriguez-Lopez,Ken-ichi Sato,J. McKenzie,Camillo Porta +19 more
TL;DR: The CLEAR trial as discussed by the authors was an open-label, multicenter, randomized, phase 3 trial of first-line treatment of advanced clear cell RCC, where patients were randomized 1:1:1 to lenvatinib 20 mg orally daily with pembrolizumab 200 mg intravenously once every 3 wk or sunitinib 50 mg daily for 4 wk.
Journal ArticleDOI
Deferred cytoreductive nephrectomy following response to ipilimumab/nivolumab, is there potential for a treatment-free interval?
Elisabeth E. Fransen van de Putte,Lianne C van den Brink,Magdy F. Mansour,Johannes C. van der Mijn,Sofie Wilgenhof,J. Van Thienen,John B. A. G. Haanen,Ekaterini Boleti,Thomas Powles,P. Zondervan,Niels M. Graafland,Alex Bex +11 more
Journal ArticleDOI
Adjuvant ipilimumab and nivolumab in renal cell carcinoma: more questions than answers
Journal ArticleDOI
IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery.
Francesca Jackson-Spence,C. Toms,Luke Furtado O'Mahony,Julia Choy,L Flanders,Bernadett Szabados,Thomas Powles +6 more
TL;DR: The IMvigor011 (NCT04660344) study as discussed by the authors is a global, double-blind, randomized phase III study assessing the efficacy of atezolizumab (anti-PD-L1) versus placebo in patients with high-risk muscle-invasive bladder cancer who are ctDNA positive post-cystectomy.
Journal ArticleDOI
1772P Characterisation of a DNA repair deficiency (DRD) biomarker phenotype in metastatic urothelial carcinoma (mUC) within the ATLANTIS clinical trial platform
Simon J. Crabb,L. Dempsey,E. Soulis,Samantha Hinsley,Y.P. Song,Jim Barber,John Frew,Joanna Gale,Guy Faust,Susannah Brock,Ursula McGovern,Omi Parikh,Deborah Enting,S. Sundar,Gihan Ratnayake,Kathryn Lees,Syed A. Hussain,Thomas Powles,R. Jones,William J. Tapper +19 more
TL;DR: Crabb et al. as discussed by the authors reported switch maintenance therapy with the PARP inhibitor rucaparib, following PBC, in patients with mUC harbouring a DRD biomarker.